NASDAQ:ALDX
Aldeyra Therapeutics Stock News
$3.93
-0.0100 (-0.254%)
At Close: Apr 26, 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, r
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
08:00am, Tuesday, 22'nd Dec 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory
Week 52 MDA Breakout Forecast - December: Short-Term Picks To Give You An Edge
05:47am, Sunday, 20'th Dec 2020
Week 52 MDA Breakout Forecast - December: Short-Term Picks To Give You An Edge
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reacti
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
08:00am, Tuesday, 08'th Dec 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript
10:19am, Thursday, 05'th Nov 2020
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript
Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6
08:00am, Wednesday, 04'th Nov 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra's novel therapeutic appro
Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation
09:22pm, Friday, 30'th Oct 2020
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly Shi ini
Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem
01:27pm, Wednesday, 02'nd Sep 2020
Allergy is a serious rising threat to the new urban lifestyle. Aldeyra’s drug might have the right answer to this problem.
Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
06:23am, Monday, 24'th Aug 2020
Two Sample Breakout Stocks for Week 35 with better than 10% short-term upside potential. Now up an average 172.2% YTD.
Aldeyra Therapeutics, Inc. (ALDX) Upgraded to Buy: Here's What You Should Know
04:00pm, Wednesday, 12'th Aug 2020
Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in Focus
02:09pm, Thursday, 06'th Aug 2020
Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
11:00am, Thursday, 06'th Aug 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?
02:07pm, Tuesday, 04'th Aug 2020
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
12:00pm, Tuesday, 04'th Aug 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the following virtual investor conferences in August:
